Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study☆

This work was supported by AstraZeneca (no grant number).

KF reports institutional honoraria or payments to Gustave Roussy Institute from Astellas, AstraZeneca, Bayer, Janssen, Merck Sharpe & Dohme (MSD), Novartis, and Sanofi; institutional participation on data safety monitoring or advisory boards for Amgen, Astellas, AstraZeneca, Bayer, Clovis, Daiichi Sankyo, Janssen, MSD, Novartis, Pfizer, and Sanofi; and personal participation on a data safety monitoring or advisory board for Arvinas, CureVac, Macrogenics, and Orion. NWC reports receiving institutional consultancy or advisory fees from Astellas Pharma, Bayer, Ferring, Janssen-Cilag, and Sanofi; speaker bureau fees from Astellas Pharma, AstraZeneca, Bayer, Janssen-Cilag, Pfizer, and Sanofi; and travel and accommodation expenses associated with lectures and advisory board meetings from Astellas Pharma, AstraZeneca, Bayer, Ferring, Ipsen, Janssen-Cilag, and Sanofi. MDS reports consulting fees and payments or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from Advanced Accelerator Applications, Amgen, Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Gilead, Immunomedics, Ipsen, Janssen, MSD, Novartis, Pfizer, Roche, Sandoz, Sanofi, Seagen, and Thermosome. MK reports payment or honoraria for lectures, presentations, speakers bureaus, and manuscript writing or educational events from AstraZeneca, MSD, and Novartis; and support for attending meetings and/or travel from MSD. CAF reports consulting fees, payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from AstraZeneca, Bayer, Merck, and Pfizer; and support for attending meetings and/or travel from Ipsen, Pfizer, and Roche. MS reports acting in a consultancy or advisory role for Adium, BMS, Johnson and Johnson, and in a speaking role for AstraZeneca, Johnson and Johnson, MSD, Pfizer and Roche. NO reports educational support and consulting/advisory board fees from AstraZeneca, Astellas, Bayer, BMS, Daiichi Sankyo, GSK, Ipsen Biopharm Limited, Johnson & Johnson, Merck/Pfizer, MSD, and The Limbic. PD reports honoraria from Astellas Pharma, Bristol Myers Squibb, Janssen, Merck Sharp & Dohme, and Roche; consulting or advisory role for Astellas Pharma, Bristol Myers Squibb, Eisai, Janssen, Merck Sharp & Dohme, and Roche; speakers’ bureau for Amgen, Astellas, BioPharma, Bristol Myers Squibb, Eisai, Janssen, Merck Sharp & Dohme, and Roche; and research funding from Janssen, Merck Sharp & Dohme, and Roche. CR, CG, MYV, and JL were AstraZeneca employees and shareholders at the time of study. DJG reports grants from Calithera, Convergence, and Corvus; grants and personal fees from Astellas, Bristol Myers Squibb, Johnson and Johnson Pharmaceuticals, Merck Sharp & Dohme, Novartis, and Pfizer; personal fees from AstraZeneca, Axess Oncology, Capio Bioscience, Flatiron, Michael J Hennessey Associates, Millennium Medical Publishing, Myovant Sciences Inc, NCI Genitourinary, Nektar Therapeutics, Physician Education Resource, Platform Q, Propella Therapeutics, RevHealth, Seattle Genetics, UroGPO, Vizuri Health Sciences, WebMD, and Xcures; grants, personal fees, and non-financial support from Bayer Healthcare Pharmaceuticals, and Exelixis Inc; personal fees and non-financial support from UroToday; and other support from the American Association for Cancer Research, all outside of the submitted work. All other authors have declared no conflicts of interest.

Data underlying the findings described in this manuscript may be obtained in accordance with AstraZeneca’s data sharing policy described at https://www.astrazenecaclinicaltrials.com/our-transparency-commitments/. Data for studies directly listed on Vivli can be requested through Vivli at https://www.vivli.org. Data for studies not listed on Vivli can be requested through Vivli at https://vivli.org/members/enquiries-about-studies-not-listed-on-the-vivli-platform/. AstraZeneca’s Vivli member page outlines further details: https://vivli.org/ourmember/astrazeneca/.